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and Rhodamine 6 G, respectively, and then with 645/65 nm and 460/50 nm filters 
to image Texas Red and both methoxy-X04 and Hoescht (on the same channel), 
all under 830 nm excitation. On the four-channel system, a secondary long-pass 
dichroic at 520 nm was followed by tertiary long-pass dichroics at 458 nm and 
one at either 562 or 605 nm. Emission was detected on four photomultiplier tubes 
through the following emission filters: 417/60 nm for Hoechst, 494/41 nm for 
methoxy-X04, 550/49 nm for Rhodamine 6 G and 641/75 nm for Texas Red. Laser 
excitation was 830 nm except when trying to image deep cortical tissue in animals 
where only Texas Red was present, in which case 900 nm excitation was used. 
Laser scanning and data acquisition were controlled by ScanImage software48. To 
visualize the cortical vasculature, stacks of images spaced at 1 μ m axially were taken 
to a cortical depth of 300–500 μ m.
For imaging of neutrophils labeled with anti-Ly6G antibodies labeled with 
Alexa488, imaging was performed on a custom-built 2PEF microscope at the 
Wellman Center for Photomedicine. In these animals, neutrophils were labeled 
with a tail vein injection of anti-Ly6G-Alexa488 (0.1 mg kg–1 animal weight, 
127626-Biolegend) at the same time as the labeling of blood plasma with Texas 
Red dextran. Imaging was done using 750 nm, 80 fs pulses from a Ti:Sapphire 
laser oscillator (Spectra-Physics Mai Tai). The laser beam was scanned by 
polygon scanners (30 frames s–1) and focused into the sample using a 40× water-
immersion objective lens for high-resolution imaging (numerical aperture of 0.80, 
Olympus), or a 10× objective for mapping of the cortical surface vasculature 
(numerical aperture of 0.30, Olympus). The emitted fluorescence was detected 
on photomultiplier tubes through the following emission filters: 525/50 nm for 
Alexa488 and 605/50 nm for Texas Red. Laser scanning and data acquis tion were 
controlled by custom-built software. Stacks of images spaced at 1 μ m axially were 
taken to a cortical depth of 100–200 μ m.
Quantification of capillary network topology and capillary segment stalling. 
The 2PEF images of vascular networks were manually traced in three dimensions 
to create a vectorized skeleton that represents the cortical vasculature using 
custom-written tracing software. The researchers producing these tracings were 
blinded to the genotype of the animal and any treatment it had received. Volumes 
of these image stacks where vessels could not be readily identified and traced were 
excluded from all analysis. These regions were typically deep and near the edges 
of the imaged volume, or occasionally directly underneath a large surface vessel. 
Vessel segments were classified as surface and penetrating arterioles and capillaries, 
or as ascending and surface venules. All vessels less than 10 µ m in diameter were 
classed as capillaries. Large-surface arterioles were distinguished from large-surface 
venules based on morphology (arterioles were of smaller diameter, had smoother 
walls and less tortuosity and tended to branch more symmetrically and in Y-shaped 
junctions compared to venules). Other arterioles or venules were classed by tracing 
their connectivity to readily identifiable large vessels.
Each capillary segment in these images was then manually classed as either 
flowing or stalled based on the motion of RBCs during the entire time each 
capillary was visible in the three-dimensional image stack. Texas Red dextran 
labels blood plasma but not blood cells, so RBCs and other blood cells are shown 
as dark patches in the vessel lumen. The motion of these dark patches indicates 
flowing blood cells. Each capillary segment was visible in a minimum of around 
five successive frames in the three-dimensional image stack, or for ~5 s (capillaries 
not oriented parallel to the cortical surface were observed for markedly more 
frames). We scored a capillary segment as stalled if we did not see motion of the 
RBCs and other cells in the capillary segment over this observation time. This 
manual scoring of capillaries, as either flowing or stalled, was performed with the 
researcher blinded to the genotype and treatment status of the animal. In addition, 
scoring was performed using only the image data visible on the Texas Red imaging 
channel. All animals included in our analysis had at least 800 capillary segments 
scored as flowing or stalled. Animals with fewer characterized capillaries  
were excluded.
Using the traced vascular network, the topologically shortest path from each 
flowing or stalled capillary to the nearest penetrating arteriole and ascending 
venule was calculated using Dijkstra’s algorithm49.
Distinguishing causes of capillary stall. In some animals, once capillary stalls 
were identified we used the additional fluorescent labels to determine what was 
blocking blood flow in the capillary segment. Stalled capillary segments with a cell-
shaped object labeled with both Rhodamine 6 G and Hoechst present were scored 
as having a leukocyte present; stalled segments with punctate objects labeled with 
Rhodamine 6 G alone were scored as having platelet aggregates; stalled capillary 
segments with only RBCs present were classed as RBC stalls. We determined what 
fraction of stalled capillaries had only a leukocyte, a leukocyte with one or more 
RBCs present, only platelet aggregates, platelet aggregates with RBCs, and only 
RBCs. With this labeling scheme, we were unable reliably to distinguish platelet 
aggregates when a leukocyte was present. Additional experiments used a low dose 
of Alexa488-labeled anti-Ly6G antibodies to assess the type of leukocyte associated 
with capillary stall.
We assessed whether the diameter of flowing and stalled capillaries was 
different, on average. First, image stacks were linearly interpolated to have 
an isotropic 1 µ m voxel size. To reduce salt-and-pepper noise in the vascular 
Methods
Animals and surgical preparation. All animal procedures were approved by the 
Cornell Institutional Animal Care and Use Committee (protocol Nos. 2009–0043 
and 2015–0029) and were performed under the guidance of the Cornell Center 
for Animal Resources and Education. We used adult transgenic mice as mouse 
models of Alzheimer’s disease, including the APP/PS1 line (B6.Cg-Tg (APPswe, 
PSEN1dE9) 85Dbo/J; MMRRC_034832-JAX, The Jackson Laboratory)45 and the 
5xFAD line (B6SJL-Tg(APPSwFlLon, PSEN1 *M146L*L286V)6799Vas/Mmjax; 
MMRRC Stock No: 34840-JAX, The Jackson Laboratory)46. Littermate WT mice 
(C57BL/6) were used as controls. Animals were of both sexes and ranged in age 
from 12 to 100 weeks.
For cranial window implantation, mice were anesthetized under 3% isoflurane 
on a custom-built stereotactic surgery frame and then maintained on ~1.5% 
isoflurane in 100% oxygen. Once unresponsive to a toe pinch, mice were given 
0.05 mg per 100 g mouse weight of glycopyrrolate (Baxter, Inc.) or 0.005 mg 
per 100 g of atropine (54925-063-10, Med-Pharmex, Inc.) to prevent lung 
secretions; 0.025 mg per 100 g of dexamethasone (07-808-8194, Phoenix Pharm, 
Inc.) to reduce post-surgical inflammation; and 0.5 mg per 100 g of ketoprofen 
(Zoetis, Inc.) to reduce post-surgical inflammation and provide post-surgical 
analgesia. Glycopyrrolate and ketoprofen were injected intramuscularly, while 
atropine and dexamethasone were injected subcutaneously. Bupivacaine (0.1 ml, 
0.125%;Hospira, Inc.) was subcutaneously administered at the incision site to 
provide a local nerve block. Animals were provided with 1 ml per 100 g mouse 
weight of 5% (w/v) glucose in normal saline subcutaneously every hour during 
the procedure. We used a thermometer and feedback-controlled heating blanket 
(40-90-8D DC, FHC) to maintain body temperature at 37 °C. The head was shaved 
and washed three times with alternating 70% (v/v) ethanol and iodine solution 
(AgriLabs). A 6 mm-diameter craniotomy was performed over the cerebral 
cortex using a high-speed drill (HP4-917-21, Fordom) using bits of diameter 1.4, 
0.9, 0.7 and 0.5 mm (Fine Science Tools) for different steps in the craniotomy 
procedure. The craniotomy was then covered with a sterile 8 mm-diameter glass 
coverslip (11986309, Thermo Scientific) and glued onto the remaining skull with 
cyanoacrylate adhesive (Loctite) and dental cement (Co-Oral-Ite Dental). All 
procedures were performed using sterile technique.
Once the craniotomy was completed, mice were returned to their cages and 
given injections of 0.025 mg per 100 g of dexamethasone and 0.5 mg per 100 g of 
ketoprofen subcutaneously 1 and 2 days after surgery, and all cages were placed 
over a heating pad during this period. Animals were given at least 2 weeks to 
recover from cranial window implantation before experimentation, to minimize 
inflammation from the surgical procedure. Animals were excluded from further 
study if the clarity of the imaging window was insufficient for 2PEF imaging.
In vivo two-photon microscopy. During imaging sessions, mice were anesthetized 
with 3% isoflurane, placed on a custom stereotactic frame and administered 
glycopyrrolate or atropine and glucose as described above. During imaging, 
anesthesia was maintained with ~1.5% isoflurane in 100% oxygen, with small 
adjustments made to the isoflurane to maintain the respiratory rate at ~1 Hz. They 
were kept at 37 °C with a feedback-controlled heating pad.
To fluorescently label the microvasculature, Texas Red dextran (40 μ l, 2.5%, 
molecular weight (MW) = 70,000 kDA, Thermo Fisher Scientific) in saline was 
injected retro-orbitally immediately before imaging. In some animals, Aβ deposits 
were labeled using methoxy-X0447. In early experiments using methoxy-X04 
obtained directly from Professor Klunk at the University of P ttsburgh, we retro-
orbitally injected 40 µ l of 1 mg ml–1 methoxy-X04 in 0.9% saline (adjusted to pH 
12.0 with 0.1 N NaOH) immediately before imaging. In later experiments using 
methoxy-X04 available commercially from Tocris, we intraperitoneally injected 
methoxy-X04 (dissolved in DMSO at 100 mM) 1 day before imaging at a dose of 
1 mg 100 g–1. We observed no obvious differences in amyloid labeling between these 
two administration approaches. In some animals, leukocytes and blood platelets 
were labeled with a retro-orbital injection of Rhodamine 6 G (0.1 ml, 1 mg ml–1 in 
0.9% saline, Acros Organics, Pure)38. Leukocytes were distinguished from blood 
platelets with a retro-orbital injection of Hoechst 33342 (50 μ l, 4.8 mg ml–1 in 0.9% 
saline, Thermo Fisher Scientific). Texas Red (and methoxy-X04, when given retro-
orbitally) was dosed in a single syringe, while Rhodamine 6 G and Hoechst were 
dosed together in a second syringe.
Three-dimensional images of the cortical vasculature and measurement of red 
blood cell flow velocity in specific vessels were obtained using a custom-built 2PEF 
microscope. Imaging was done using 830 nm, 75 fs pulses from a Ti:Sapphire laser 
oscillator (MIRA HP pumped by a Verdi-V18 or Vision S, Coherent) and 900 nm, 
75 fs pulses from a second Ti:Sapphire laser oscillator (Vision S, Coherent). Lasers 
were scanned by galvonometric scanners (1 frame s–1) and focused into the sample 
using a 20× water-immersion objective lens for high-resolution imaging (numerical 
aperture of 1.0, Carl Zeiss Microscopy; or numerical aperture of 0.95, Olympus), or 
a 4× objective for mapping of the cortical surface vasculature (numerical aperture 
of 0.28, Olympus). The emitted fluorescence was detected on either a two-channel 
detection system or, for later datasets, an upgraded four-channel detection system. 
On the two-channel system, the fluorescence was split by a 600 nm-long-pass 
dichroic and two successive image stacks were acquired first with 645/45 nm 
(center wavelength/bandwidth) and 575/25 nm bandpass filters to image Texas Red 
an alternating trial. Because the maximum number of triads is the total number of 
arm entries minus 2, the spontaneous alternation score was calculated as ([number 
of alternating triads]/([total number of arm entries] − 2)).
Novel object recognition test. The NOR task measures recognition memory and 
is based on rodents’ innate preference for exploring novel objects. This test was 
conducted only at baseline and after 4 weeks of treatment. The testing approach 
was identical to the object replacement task, but with a novel object placed at 
the location of one of the initial objects in trial 2. To exclude preference bias for 
particular objects in the first trial, one animal would see two of object A and 
another animal two of object B. In the second trial, to test for preference for a novel 
object, both animals saw one of object A and one of object B. For the repeat of the 
test at 4 weeks, we used new objects C and D.
ELISA assay. After the conclusion of the behavior experiments, the APP/PS1 
animals that had received α -Ly6G or isotype control antibodies every 3 days for a 
month were killed by lethal injection of pentobarbital (5 mg per 100 g). Brains were 
quickly extracted and divided along the centerline. One half was immersed in 4% 
paraformaldehyde in phosphate buffered saline (PBS) for later histological analysis 
and the other half was snap-frozen in liquid nitrogen.
The frozen APP/PS1 mouse hemi-brains (Iso-Ctr: n = 6, 11.5–12.5 months 
old; α -Ly6G: n = 7, 11.5–12.5 months old) were weighed and homogenized in 
1 ml PBS containing complete protease inhibitor (Roche Applied Science) and 
1 mM AEBSF (Sigma) using a Dounce homogenizer. The homogenates were then 
sonicated and centrifuged at 14,000 g for 30 min at 4 °C. The supernatant (PBS-
soluble fraction) was removed and stored at − 80 °C. The pellet was re-dissolved 
in 0.5 ml 70% formic acid, sonicated and centrifuged at 14,000 g for 30 min at 4 °C, 
and the supernatant was removed and neutralized using 1 M Tris buffer at pH 11.0. 
Protein concentration was measured in the PBS-soluble and formic acid-soluble 
fractions using the Pierce BCA Protein Assay (Thermo Fischer Scientific). The 
PBS-soluble fraction extracts were diluted 1:5; formic acid extracts were diluted 
1:1 after neutralization. These brain extracts were analyzed by sandwich ELISA 
for Aβ 1–40, Aβ 1–42 and Aβ aggregates using commercial ELISA kits and following 
the manufacturer’s protocol (Aβ 1–40: KHB3481; Aβ 1–42: KHB3441; Aβ aggregates: 
KHB3491, Thermo Fisher Scientific). The Aβ concentration was calculated by 
comparing sample absorbance with that of known concentrations of synthetic Aβ 1–40  
and Aβ 1–42 standards on the same plate. Data were acquired with a Synergy  
HT plate reader (Biotek) and analyzed using Gen5 software (BioTek) and  
Prism (Graphpad).
Statistical analysis. Boxplots were created using Prism7 (GraphPad). The box 
extends between the values for the 25th and 75th percentiles of the data. The 
whiskers extend 1.5 times the difference between the values of the 75th and 25th 
percentiles of the data from the top and bottom of the box. Values lying outside 
the whiskers were defined as outliers, and the mean was computed excluding these 
outliers. The median is indicated with a black horizontal line inside the box, while 
the mean is indicated with a red horizontal line. Violin plots were created using the 
statistical software package R.
Data in all groups were tested for normality using the D’Agostino–Pearson 
omnibus normality test. Parametric statistics were used only if the data in all 
groups in the comparison were normally distributed. The statistical significance 
of differences between multiple groups was determined using one-way ANOVA 
followed by Tukey’s multiple comparison correction for normally distributed 
data, and using one-way Kruskal–Wallis ANOVA followed by Dunn’s multiple 
comparison correction for data with non-normal distribution. To compare baseline 
and post-treatment measurements at multiple time points with non-normal data, 
Friedman one-way repeated measures non-parametric ANOVA followed by 
Dunn’s multiple comparison correction was used. Statistical comparisons between 
two groups were performed using Student’s t-test or paired t-test for normally 
distributed data, or with the Mann–Whitney test or Wilcoxon matched-pairs 
test for data with non-normal distribution. P < 0.05 was considered statistically 
significant. All statistical analysis was performed using Prism7 (GraphPad).
We use a standardized set of significance indicators across all figures 
in this manuscript. For comparisons between groups: *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001. For matched comparisons before and after 
treatment: +P < 0.05, ++P < 0.01. Details of the groups compared, animal and 
capillary numbers, sex distributions statistical tests, exact P values and explanatory 
notes for individual panels are included in the figure captions.
Additional methodological details. Additional information on the methods used 
in this study is available in the Supplementary Methods.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Code availability
Code for 3D tracing, vessel segmentation, analysis of linescan data and 
determination of amyloid density around capillaries can be obtained by contacting 
images, we filtered using a three-dimensional 5 × 5 × 5 pixel Gaussian filter. 
We then corrected for unevenness in the image intensity by filtering the image 
(85 × 85 pixel-sized mean filter) and subtracted this from the Gaussian filtered 
image. The resulting image was binarized using Otsu’s method50. Finally, objects 
smaller than 1,000 voxels were eliminated, where voxels were considered part of 
the same connected object whenever they shared at least one corner. We then used 
this binarized image to correct the manual tracing of the vasculature by shifting the 
centerline so that it was equidistant from the vessel boundaries (done within  
a 10 µ m neighborhood to avoid confusion between neighboring capillaries).  
Every 5 µ m along the centerline of each capillary segment, we estimated the  
vessel radius by finding the shortest distance from the centerline to the vessel 
boundary. Measurements < 2 µ m or > 10 µ m were excluded, as these probably 
reflected imaging artifacts, and we averaged across all measurements for  
each capillary segment.
Administration of antibodies against Ly6G or LFA-1 to interfere with capillary 
stalling. We treated APP/PS1 and 5xFAD mice with intraperitoneal injections of 
monoclonal antibodies against lymphocyte antigen 6 complex, locus G (Ly6G)  
(α -Ly6G, clone 1A8, 4 mg kg–1, BD Biosciences) or an isotype control antibody 
(Rat IgG2a, κ , 4 mg kg–1, BD Biosciences). In addition, APP/PS1 mice were treated 
with retro-orbital or intraperitoneal injections of monoclonal antibodies against 
lymphocyte functional antigen 1 (α -LFA-1; M17/4 clone, BD Biosciences; 4 mg kg–1). 
The same cortical capillary bed was imaged in anesthetized mice immediately 
before and at 60–90 min after treatment. Mice were randomly assigned to receive 
treatment or isotype control antibodies, and the experimenter was blinded to both 
mouse genotype and whether the antibody was the treatment or control during 
the experiment. Quantification of stalled capillaries was performed by researchers 
blinded to imaging time, animal genotype and treatment type.
Behavior experiments. All experiments were performed under red lighting in an 
isolated room. The position of the mouse’s nose was automatically traced by Viewer 
III software (Biobserve). In add tion to the automatic results obtained by Viewer III 
software, a blinded experimenter independently scored mouse behavior manually. 
Animals were taken into the behavior room 1 h before the experiment. Behavioral 
analysis was conducted at baseline and at 3 and 24 h after injection with α -Ly6G, 
α -LFA-1 or isotype control antibodies (IP 4 mg kg–1). The α -Ly6G-treated APP/
PS1 mice were then treated every 3 days for 4 weeks (2 mg kg–1intraperitoneally) 
and behavior experiments were repeated. The object replacement, Y-maze, balance 
beam walk and forced swim tests were performed at all time points. The NOR 
task was performed only at baseline and the 4-week time point, to avoid animals 
becoming accustomed to the objects. For experiments with APP/PS1 mice and 
α -Ly6G, animals were ~11 months of age at the start of the experiment. For 
experiments with APP/PS1 mice and α -LFA-1, animals were 11–13 months of age. 
For experiments with 5xFAD mice and α -Ly6G, animals were 5–6 months of age. 
Mice were randomly assigned to receive treatment or isotype control antibodies, 
and the experimenter was blinded to both mouse genotype and whether the 
antibody was the treatment or control during the experiment.
Object replacement test. The object replacement task evaluated spatial memory 
performance. All objects used were first validated in a separate cohort of mice to 
ensure that no intrinsic preference or aversion was observed, and animals explored 
all objects similarly. Exploration time for the objects was defined as any time 
when there was physical contact w th an object (whisking, sniffing, rearing on or 
touching it) or when the animal was oriented toward the object and the head was 
within 2 cm of it. In trial 1, mice were allowed to explore two identical objects for 
10 min in the arena and then returned to their home cage for 60 min. Mice were 
then returned to the testing arena for 3 min with one object moved to a novel 
location (trial 2). Care was taken to ensure that the change of placement altered 
both the intrinsic relationship between objects (for example, rotation of the moved 
object) and the position relative to internal visual cues (for example, new location 
in the arena; one wall of testing arena had a pattern). At subsequent time points, 
new object positions and new pairs of objects (from the validated pool of objects) 
were used to maintain animal interest. In addition to using the tracking software to 
determine the object exploration times, the time spent at each object was manually 
scored by an independent experimenter who was blinded to the genotype and 
treatment. The preference score (%) for object replacement tasks was calculated, 
from the data in trial 2, as ([exploration time of the novel object]/[exploration time 
of both objects]) × 100. Automated tracking and manual scoring yielded similar 
results across groups, so we report the automated tracking results.
Y-maze. The Y-maze task was used to measure working memory, by quantifying 
spontaneous alternation between arms of the maze. The Y-maze consisted of three 
arms at 120° and was made of light gray plastic. Each arm was 6 cm wide and 36 cm 
long, and had walls 12.5 cm in height. The maze was cleaned with 70% ethanol 
after each mouse. A mouse was placed in the Y-maze and allowed to explore for 
6 min. Behavior was monitored, recorded and analyzed using the Viewer software. 
A mouse was considered to have entered an arm if the whole body (except for the 
tail) entered it, and to have exited if the whole body (except for the tail) exited the 
arm. If an animal consecutively entered three different arms, that was counted as 
N.N. or C.B.S. Code for simulation of blood flow in vascular networks can be 
obtained by contacting S.L.
Data availability
The raw data reported in this manuscript are archived at https://doi.
org/10.7298/9PR3-D773.
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Reporting Summary
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one  or two sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Software and code
Policy information about availability of computer code
Data collection All in vivo mouse data  was taken with a custom built 2 photon microscope, Biospec 70/30, Bruker and custom built laser speckle setup.  
Histology sections have been analyzed by a Zeiss Examiner.D1 AXIO, behavioral data was collected using ViewerIII from BIOBSERVE 
(Germany), scanimage (Vidrio Tech.), and flow cytometry data was taken on a Guava easyCyte Flow Cytometer (EMD Millipore 
Corporation).
Data analysis Data has been analyzed using MATLAB  (The MathWorks, Inc), ImageJ (NIH), FlowJo (LLC), Gen5 (BioTeck), Imaris 8 (Bitplane), R 3.5.1 
(The R Foundation), G*Power, and Prism7 (GraphPad).
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
 Accession codes, unique identifiers, or web links for publicly available datasets 
 A list of figures that have associated raw data 
 A description of any restrictions on data availability
The data reported in this manuscript are archived at https://doi.org/10.7298/9PR3 D773.
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Sample size In most cases, sample sizes for comparisons across groups were determined from power analysis calculations. The data on capillary stall 
incidence in Fig. 1c and d in APP/PS1 vs. wt mice is significantly overpowered, as this data includes experiments that yielded the initial 
discovery of elevated capillary stalling in APP/PS1 mice as well as all subsequent baseline data. For measurements of the cellular cause of 
capillary stalls (Fig. 2a and b), we anticipated finding ~20 stalls per mouse (~2% of 1,000 characterized capillaries). Assuming each possible 
stall cause was equally likely and wanting to resolve these percentages to +/ 10% at a 95% confidence interval, then binomial statistics implied 
the need for ~100 capillary stalls, or about five mice. For 2PEF measurements of penetrating arteriole blood flow (Fig. 3b and c), ASL MRI 
measurements of cortical perfusion (Fig. 3d and e), and behavioral experiments (Fig. 4) comparing APP/PS1 and wt mice before and after 
antibody treatment, we used a matched pairs study design, estimates of measurement variability from published and preliminary data, and 
estimates of minimal biologically relevant effect size to determine minimum group sizes using G*Power. This yielded minimum group sizes of 
5 mice for 2PEF measurements of penetrating arteriole blood flow and 10 mice for ASL MRI and behavioral experiments. In subsequent 
experiments with other mouse models and other treatments we continued using these group sizes.
Data exclusions Animals were excluded from further study if the clarity of the imaging window was insufficient for 2PEF imaging. All animals included in our 
analysis of the frequency of capillary stalling had at least 800 capillary segments scored as flowing or stalled. Animals with fewer characterized 
capillaries were excluded. 
Replication Experiments to determine the fraction of capillaries stalled and the cell type responsible for stalls have been conducted by several different 
experimenters across different microscopes, and even different laboratories. The manual scoring of capillaries as flowing or stalled was 
performed with the researcher blinded to the genotype and treatment status of the animal. 
Blood flow experiments (line scans,  ALS MRI, and Laser Speckle Imaging) were conducted and analyzed with the experimenter blinded to the 
treatment and genotype of the animals.   
Behavior experiments in APP/PS1 mice were done twice with two independent groups with similar results. The experimenter was blinded to 
the treatment and animal genotype. In addition to the automatic results we obtained, a blinded experimenter independently scored mouse 
behavior manually. All manual and automated analysis results concurred. 
Randomization Animals were matched by age and similar numbers of male and female animals were used in nearly all comparisons. Controls were litter 
mates. Mice were randomly selected for treatment or control groups. All treatments were given by a different researcher where possible to 
ensure blinding. 
Blinding During experiments comparing the impact of treatments, the experimenter was blinded to the treatment and genotype of the mouse. All 
analysis was conducted with the experimenter blinded to the genotype, treatment, and time point of the data. Image processing was done 
also blinded to genotype and treatment, if possible (note that AD mouse models can be readily distinguished at some ages by presence of 
amyloid plaques). 
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Methods
n/a Involved in the study
ChIP seq
Flow cytometry
MRI based neuroimaging
Antibodies
Antibodies used Antibodies: 
Antibodies were  validated in preliminary experiments involving serial dilutions (Ly6G).  The final concentration used for each 
antibody is: 
Ly6G (for in vivo imaging): clone 1A8, Alexa 488 labeled, Catalog No.560257,  BD Biosciences 
Ly6G (for in vivo blocking of adherence):clone 1A8, FITC labeled, Catalog No.551460, BD Biosciences 
LFA 1: clone M17/4, CD11b, Catalog No. 550528 BD Biosciences 
Iso Ctr: clone IgG2a, k, Catalog No. 553387, BD Biosciences 
in vivo imaging: 
Ly6G antibodies (0.1 mg/kg), i.v. injection 
Blocking adherence or causing depletion: 
acute experiments: Ly6G or isotype control antibodies (4 mg/kg), i.p. injection 
chronic experiments: Ly6G or isotype control antibodies (2 mg/kg), i.p. injection 
LFA 1 experiments: LFA 1 or saline control injection (4 mg/kg), retro orbital injection (blood flow expts.) or i.p. injection 
(behavioral expts.) 
Flow cytometry: 
Chronic experiments: 24h after Ly6G or control injection (4 mg/kg), i.p. injection 
Neutrophil determination: anti CD45 (Catalog No.5560695, BD Bioscience), anti CD11b (Catalog No.561690, BD Bioscience) and 
anti Ly6G (551460, BD Bioscience). 
Histology: 
Chronic treatment experiment: Sections have been incubated with 1% Thioflavin S (T1892, Sigma) for 10 min at room 
temperature and washed twice with 80% ethanol for 2 min and counter stained with and 1:5000 DAPI (Sigma)
Validation Ly6G (for in vivo imaging) has been validated for example in: Journal of Experimental Medicine Apr 2012, 209 (4) 819 835; DOI: 
10.1084/jem.20112322 
Ly6G (for in vivo blocking of adherence):clone 1A8, FITC labeled, BD Biosciences, has been used widely for flow cytometry and in 
vivo imaging:  Journal of Immunology Research, 2018, (1), (2018) 
LFA 1: clone M17/4 has been used for in vivo studies and behavioral studies for example in Nature Medicine volume 21, pages 
880 886 (2015) 
CD45  widely used and validated references  on the BD Biosciences web page 
CD11b widely used and validated references on the BD Biosciences web page 
Iso Ctr: clone IgG2a, k, BD Biosciences targets an unknown sequence 
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals Heterozygous APP/PS1 mice have been used in this study (The Jackson Laboratory (Bar Harbor, ME)). These mice over express 
the amyloid precurser protein (APP) (Mo/HuAPP695swe) together with the human muted presenilin 1 (PS1 dE9) gene driven 
under the prion (PrP) promoter. 
As a second mouse model we used  TgCRND8  that over expresses the APP gene 695 (KM670/671NL+V717F) under the PrP 
promoter. 
As a third mouse model we used 5xFAD mice (The Jackson Laboratory) that overexpress APP with the following mutations 
(Swedish (K670N, M671L), Florida (I716V), and London (V717I)) along with mutated PS1 with the following mutations (M146L 
and L286V), under the Thy1 promoter. 
12 90 weeks old male and female (APP/PS1 n=28 and wild type n=12) mice have been used for the analyses done in figure 1. 
Antibody injected animals to determine blood flow and number of stalls after Ly6G treatment have been male and female APP/
PS1 mice 3 4 month:  APP/PS1, α Ly6G n=5; APP/PS1 Iso Ctl, n=5;and wt α Ly6G, n=5; 11 14 month: APP/PS1, α Ly6G n=3; and 
APP/PS1 Iso Ctl, n=3) 
ALS MRI has been performed with 7 9 month old male and female APP/PS1 mice (APP/PS1, α Ly6G n=10; APP/PS1 Iso Ctl, n=10; 
and wt α Ly6G, n=10) 
Capillary stalls and flow in 5xFAD mice: 5 7 months of age, wt α Ly6G: 3 mice; 5xFAD Iso Ctr: 3 mice,; and 5xFAD α Ly6G: 3 mice. 
Behavior experiments used 11 month old APP/PS1 male and female animals have been used (APP/PS1, α Ly6G n=11; APP/PS1 
Iso Ctl, n=9; wt α Ly6G, n=10; and wt Iso Ctl, n=10). Brains for the ELISA and histology experiments has been  from the the ones 

Turbo RARE anatomical images were acquired with the following parameters: 10 averages of 14 slices with the same 
field of view and orientation as the ASL images, resolution = 0.078 × 0.078 × 1 mm3, TE = 48 ms, TR = 2000 ms, and a 
RARE factor of 10
Area of acquisition Anatomical localizer images were acquired to find the transversal slice at a location approximately corresponding to 
Bregma 0.94 mm 
Diffusion MRI Used Not used
Preprocessing
Preprocessing software For computation of rCBF, the Bruker ASL perfusion processing macro was used. It uses the model of Kober, et al., and 
includes steps to mask out the background and ventricles. The masked rCBF images were exported to Analyze format on 
the MRI console. Statistics has been finalized in PRISM.  
F. Kober et al., High resolution myocardial perfusion mapping in small animals in vivo by spin labeling gradient echo 
imaging. Magnetic resonance in medicine 51, 62 67 (2004).
Normalization n/a
Normalization template n/a
Noise and artifact removal n/a
Volume censoring Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.
Statistical modeling & inference
Model type and settings Our primary comparisons are between the baseline measurements for wild type and AD mouse models (t test, as data 
were normally distributed), and a paired comparision of wt or AD mice before and after antibody treatment (paired t
test, data were normally distributed). 
Effect(s) tested Measured cerebral blood flow in the same mice before and after treatment. Secondary measure comparing blood flow 
in wt and AD mice. 
Specify type of analysis: Whole brain ROI based Both
Anatomical location(s)
The masked CBF images were exported to Analyze format on the MRI console. We then used the 
anatomical image to create a mask that outlined the entire cortical region,excluding the sinus, and 
averaged the CBF measurement across this region for each animal at each imaging time point. Analysis of 
ASL MRI data was conducted blinded to animal genotype and treatment.
Statistic type for inference
(See Eklund et al. 2016)
voxel wise
Correction n/a
Models & analysis
n/a Involved in the study
Functional and/or effective connectivity
Graph analysis
Multivariate modeling or predictive analysis
